drugset / Trial / NCT00933231

Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts

NCT00933231

RandomizedFactorialOpen-labelTreatment

Summary

This is a multicentre study examining the use of Advagraf-minimization strategy and/or the use of an inhibitor of the renin-angiotensin system in reducing chronic rejection in renal allografts.

Timeline

Start
2009-08-17
Primary completion
2015-05-11
Completion
2018-04-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Irbesartan Small molecule Oral
Subject Ramipril Small molecule Oral
Subject Tacrolimus Small molecule Oral
Background Basiliximab Monoclonal antibody
Background Methylprednisolone Other / unclassified Intravenous
Background Mycophenolate Mofetil Small molecule Oral
Background Prednisone Other / unclassified Intravenous

Indications

No indication recorded.